You are viewing: US AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The US AI in Life Science Market was valued at $9477.4 Million in 2026 and projected to reach to $29746.2 Million by 2031, representing a compound annual growth rate of 25.7%. The US AI in Life Science Market is poised for exceptional growth through 2031, driven by substantial investments from pharmaceutical giants, biotech startups, and healthcare institutions seeking competitive advantages in drug development and patient care.

US AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US AI in Life Science Market Trends and Insights

  • This represents a compound annual growth rate of 25.7%, driven by increasing adoption of artificial intelligence across drug discovery, clinical trials, and personalized medicine in the US healthcare sector.
  • The US maintains a leadership position in AI-enabled life science innovation, supported by robust R&D investments, advanced computational infrastructure, and a concentration of biotechnology and pharmaceutical companies. US market growth is fueled by accelerating digital transformation in life sciences, regulatory support for AI-driven therapeutics, and rising demand for precision medicine solutions.
  • Between 2026 and 2031, the US market is expected to more than triple in value, reflecting the critical role AI plays in reducing time-to-market for new drugs and improving patient outcomes.
  • The US continues to attract significant venture capital and corporate investment in AI life science startups, positioning the country as the global epicenter for this emerging market segment..

Key Market Statistics

  • CAGR (2026-2031) 25.7% CAGR
  • Market Size, 2026 ~USD 9477.4 Million
  • Forecast, 2031 ~USD 29746.2 Million
  • Country US

US AI in Life Science Market Overview

Market Valuation Growth :

The US AI in Life Science Market is valued at $9,477.4 million in 2026 and is projected to reach $29,746.2 million by 2031, representing a 214% increase over the five-year forecast period.

Robust CAGR Performance :

The US market is growing at a 25.7% CAGR from 2026 to 2031, outpacing many other healthcare technology segments and reflecting strong investor confidence and adoption rates across the life sciences sector.

Drug Discovery & Clinical Trials Leadership :

US pharmaceutical and biotech companies are leveraging AI for accelerated drug discovery, clinical trial optimization, and patient recruitment, positioning the country as a global innovation hub in AI-driven life sciences.

Personalized Medicine Expansion :

American healthcare providers are increasingly implementing AI-powered personalized medicine solutions, enabling precision diagnostics and tailored treatment plans that improve patient outcomes and reduce healthcare costs.

US AI in Life Science Market Dynamics

  • Regulatory support from the FDA and increasing venture capital funding are accelerating AI adoption across the life sciences value chain.
  • The convergence of advanced computing infrastructure, large-scale genomic datasets, and skilled AI talent positions the US as the dominant market leader.
  • Healthcare organizations are prioritizing AI implementations to reduce time-to-market for therapeutics, enhance clinical trial efficiency, and enable data-driven decision-making.
  • This trajectory reflects the US healthcare sector's commitment to innovation and digital transformation..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • The US AI in Life Science Market will grow from $9.48B in 2026 to $29.75B in 2031 at a 25.7% CAGR.
    • The US leads global AI adoption in drug discovery, clinical trials, and personalized medicine applications.
    • Strong US regulatory frameworks and venture capital ecosystem accelerate AI life science innovation and commercialization.
    • The US market is expected to more than triple in value over the five-year forecast period, driven by digital transformation.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    US AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    US: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES406497.7622.4782.7972.91220.81522.21876.524.7
    BIOTECHNOLOGY COMPANIES1480.41838.823302968.93739.247546006.17502.326.3
    CRO & CDMO1044.81283.21607.92025.92522.93171.83962.34894.124.9
    DIAGNOSTIC COMPANIES618.5765.39661226.11538.21948.12451.63050.425.9
    OTHER END USERS127.8153.4187.3229.6277.6338407.8485.121
    PHARMACEUTICAL COMPANIES2405.72979.23763.84781.46003.97610.39585.711937.726
    TOTAL6083.27517.59477.412014.615054.71904323935.729746.225.7

    Target Audience

    • Pharmaceutical & Biotech Executives : C-suite leaders and R&D directors need market intelligence to justify AI investments, accelerate drug discovery timelines, and maintain competitive advantage in the rapidly evolving US life sciences landscape.
    • Healthcare Technology Investors : Venture capitalists, private equity firms, and institutional investors require detailed market data to identify promising AI life science startups, assess portfolio company performance, and optimize investment returns.
    • Healthcare Providers & Hospital Systems : Chief Medical Officers and digital health leaders need insights into AI adoption trends for personalized medicine and clinical operations to improve patient outcomes and operational efficiency across US healthcare networks.
    • AI & Software Solution Providers : Enterprise software vendors and AI platform companies need market segmentation data to tailor solutions for US life sciences customers, identify emerging use cases, and forecast revenue opportunities.
    • Regulatory & Policy Advisors : Government agencies, compliance consultants, and policy organizations require market analysis to understand AI adoption rates, regulatory gaps, and industry trends shaping the future of US life sciences innovation.

    Key Companies in the US AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Strategic Market Sizing : Obtain precise valuation data for the US market ($9.5B in 2026) and detailed forecasts through 2031 to inform capital allocation, M&A strategies, and market entry decisions with confidence.
    • Competitive Intelligence : Understand the US competitive landscape, identify leading players in AI-driven drug discovery and clinical trials, and benchmark your organization's positioning against market leaders.
    • Growth Opportunity Identification : Leverage the 25.7% CAGR insight to identify high-growth segments within personalized medicine, diagnostics, and therapeutic development where investment and innovation will yield maximum returns.
    • Regulatory & Investment Insights : Access analysis of FDA regulatory trends, venture capital funding patterns, and policy drivers shaping the US AI life science ecosystem to anticipate market shifts and regulatory requirements.
    • Customer & Partner Strategy : Develop targeted go-to-market strategies for US pharmaceutical companies, biotech firms, and healthcare providers by understanding their AI adoption priorities and pain points in drug development and patient care.

    Frequently asked questions

    What is the current size of the US AI in Life Science Market?

    The US AI in Life Science Market is valued at $9,477.4 million in 2026 and is projected to reach $29,746.2 million by 2031.

    What is the growth rate of the US AI in Life Science Market?

    The US AI in Life Science Market is growing at a compound annual growth rate (CAGR) of 25.7% from 2026 to 2031.

    What are the primary drivers of growth in the US market?

    Key drivers include accelerating digital transformation in life sciences, regulatory support for AI-driven therapeutics, rising demand for precision medicine, and substantial venture capital investment in US-based AI life science startups.

    Why does the US dominate the global AI in Life Science Market?

    The US leads due to robust R&D investments, advanced computational infrastructure, concentration of biotechnology and pharmaceutical companies, supportive regulatory environment, and a thriving venture capital ecosystem.

    How much will the US market grow by 2031?

    The US AI in Life Science Market is expected to more than triple in value, growing from $9.48B in 2026 to $29.75B in 2031, representing a $20.27B increase over five years.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status